all

Health groups ask India to rescind Gilead's patents for COVID-19 drug remdesivir

Reading now: 144
www.livemint.com

New Delhi: Two health advocacy groups have written to the Indian government asking it to rescind patents given to Gilead Sciences for the drug remdesivir so it can be distributed more fairly to coronavirus patients around the world, particularly in poorer nations.

Drug patents in India are an important issue as many countries depend on generic drugmakers to make and sell cheaper versions of critical drugs to them.

Gilead's three patents in India for remdesivir stem from 2009 when the drug was in development to treat Ebola. Remdesivir is the only drug approved to treat COVID-19 patients after promising early trial results prompted US regulators to grant emergency use authorisation on May 2.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA